Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants

ELGN-2112 has the potential to be the first innovative therapeutic treatment for intestinal malabsorption in preterm neonates Elgan Pharma and Chiesi Farmaceutici S.p.A are collaborating to develop ELGN-2112 NAZARETH, Israel and PARMA, Italy, June 5, 2025 /PRNewswire/ -- Elgan Pharma Ltd....

Read More